Drugs/Recall·openFDA/drug

Amneal Pharmaceuticals, LLC — Class II: Estradiol Gel, 0.1%, 0.25 mg, 30-packets per carton, Rx only, Distributed by: Amneal Pharm

MediumPublished Oct 7, 2026· AI-analyzed Oct 13, 2026View original FDA source
AI-generated regulatory interpretation. The four sections below are an analyst-style summary produced by an AI model from the original FDA source. Always verify against the source before any regulatory, clinical, or commercial decision.
What happened

Amneal Pharmaceuticals, LLC has initiated a Class II recall for Estradiol Gel, 0.1% (0.25 mg) due to defective containers, specifically packets that were found to be empty or only partially full.

Who it affects

This recall affects Amneal Pharmaceuticals, LLC, distributors of NDC 69238-2452-3, and quality/manufacturing personnel responsible for topical gel sachet production and weight verification.

Why it matters

Empty or partially full packets lead to sub-therapeutic dosing, which is a significant clinical concern for prescription hormone therapies. From a regulatory perspective, this suggests a failure in automated fill-weight monitoring or final container-closure integrity checks during the packaging process. The ongoing status indicates that reconciliation and root cause analysis may still be in progress.

Practical takeaway

QA teams should review in-process weight-check protocols for sachet/packet filling lines to ensure detection of under-filled or empty units. Manufacturing teams should investigate potential equipment calibration errors or sensor failures that allowed empty primary packaging to reach final carton assembly.

FDA source material

Class II. Reason: Defective Container; packets were found to be either empty or partially full.. Product: Estradiol Gel, 0.1%, 0.25 mg, 30-packets per carton, Rx only, Distributed by: Amneal Pharmaceuticals LLC, Bridgewater, NJ 08907, NDC 69238-2452-3.. Firm: Amneal Pharmaceuticals, LLC (Bridgewater NJ United States). Status: Ongoing.

Open in openFDA / FDA.gov
AI-generated interpretation. Always verify critical decisions against the original FDA source. Generated with google/gemini-3-flash-preview.